Acceleron Pharma Company Profile (NASDAQ:XLRN)

About Acceleron Pharma (NASDAQ:XLRN)

Acceleron Pharma logoAcceleron Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics to treat serious and rare diseases. Its research focuses on key natural regulators of cellular growth and repair, particularly the Transforming Growth Factor-Beta (TGF-beta), protein superfamily. It has four internally discovered therapeutic candidates that are in clinical trials, which include luspatercept, sotatercept, dalantercept and ACE-083. It offers a platform technology, IntelliTrap. It is also evaluating ACE-1332, a selective TGF-beta antagonist, for treatment of disorders with a fibrotic component, and additional molecules from its IntelliTrap platform for undisclosed therapeutic areas. Dalantercept is designed to treat cancers by inhibiting blood vessel formation by inhibiting signaling through the ALK1 receptor. ACE-083 is designed to promote muscle growth and function in specific, targeted muscles.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $975.08 million
  • Outstanding Shares: 38,617,000
Average Prices:
  • 50 Day Moving Avg: $28.74
  • 200 Day Moving Avg: $28.67
  • 52 Week Range: $23.07 - $41.69
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.22
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $13.27 million
  • Price / Sales: 73.48
  • Book Value: $5.40 per share
  • Price / Book: 4.68
  • EBIDTA: ($86,120,000.00)
  • Net Margins: -229.77%
  • Return on Equity: -30.75%
  • Return on Assets: -26.64%
  • Current Ratio: 8.96%
  • Quick Ratio: 8.96%
  • Average Volume: 403,959 shs.
  • Beta: 1.73
  • Short Ratio: 7.03

Frequently Asked Questions for Acceleron Pharma (NASDAQ:XLRN)

What is Acceleron Pharma's stock symbol?

Acceleron Pharma trades on the NASDAQ under the ticker symbol "XLRN."

How were Acceleron Pharma's earnings last quarter?

Acceleron Pharma Inc (NASDAQ:XLRN) issued its quarterly earnings results on Monday, May, 8th. The company reported ($0.66) earnings per share for the quarter, missing the consensus estimate of ($0.58) by $0.08. The business earned $3.71 million during the quarter, compared to analysts' expectations of $3.38 million. Acceleron Pharma had a negative return on equity of 30.75% and a negative net margin of 229.77%. The company's quarterly revenue was down 79.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.13 earnings per share. View Acceleron Pharma's Earnings History.

Where is Acceleron Pharma's stock going? Where will Acceleron Pharma's stock price be in 2017?

15 brokers have issued 1 year price targets for Acceleron Pharma's shares. Their forecasts range from $20.00 to $63.00. On average, they anticipate Acceleron Pharma's stock price to reach $44.23 in the next year. View Analyst Ratings for Acceleron Pharma.

What are analysts saying about Acceleron Pharma stock?

Here are some recent quotes from research analysts about Acceleron Pharma stock:

  • 1. According to Zacks Investment Research, "Acceleron Pharma Inc. is a biopharmaceutical company which focuses on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. Acceleron Pharma Inc. is based in Cambridge, Massachusetts. " (5/11/2017)
  • 2. Instinet analysts commented, "We are initiating coverage of Acceleron (XLRN) with a Buy rating and $58 target price. We recommend owning XLRN shares ahead of what we view as underappreciated 2H17 readouts. We foresee upside to the shares following positive results in 2H17 from a Phase 2 study of ACE-083, a myostatin+ inhibitor in FSHD. ACE-083 is a wholly owned program that is not currently ascribed value in XLRN's share price but worth $19/sh, by our estimate. We believe that these near-term data have been obscured by investors' focus on pivotal 2H18 Phase 3 results from Celgene-partnered (20-25% royalties) blockbuster luspatercept in MDS and beta-thalassemia. We expect further share price appreciation from this program in 2H17, as Phase 2 extension data for luspatercept better frames the magnitude of, and potential upside to, the market opportunity from indication expansion in myeloid diseases outside beta-thalassemia and MDS." (3/1/2017)
  • 3. Credit Suisse Group AG analysts commented, "We view Mr Dable’s prior role as President of US Pharmaceuticals Bayer and experience in commercial product launches as a strong strategic fit for XLRN’s future commercialization. Further, Mr Dable brings significant collaboration experience from Bayer deals with Genzyme and Regeneron, where he spearheaded ophthalmology business planning and execution. Our conversation with mgmt. indicates Dr. Knopf will stay involved with XLRN in a scientific capacity, after co-founding the company 13 years ago. Mgmt change prepares XLRN for luspatercept co-commercialization: With ph3 trials in MDS and beta-thalassemia ongoing, we see Mr. Dable bringing significant commercial experience to XLRN. We conservatively model luspatercept sales in ESA-resistant and ring sideroblast-positive (RS+) MDS patients (ph3 MEDALIST population) and transfusion dependent beta- thalassemia patients (ph3 BELIEVE population). We model PoS-unadjusted peak year sales ests. of $908M globally in MDS and $1.1B in beta- thalassemia." (9/28/2016)
  • 4. FBR & Co analysts commented, "Acceleron Pharma announced preliminary updated positive data from the ongoing Phase II trials with luspatercept in myelodysplastic syndromes (MDS) and beta- thalassemia that are being presented at the 21st Congress of the EHA. The main takeaway from the beta-thalassemia data, in our opinion, is that 67% (20/30) and 83% (20/24) of transfusion-dependent (TD) patients achieved a ≥33% reduction of transfusion burden from 12 weeks pre-treatment to 12 weeks on treatment in the base and extension study, respectively. In the ongoing extension study, 50% (11/22) of patients with lower-risk MDS who were eligible for transfusion independence (TI) achieved red blood cell transfusion independence (RBC-TI) ≥ 8 weeks (range nine to more than 80 weeks)." (6/13/2016)

Who are some of Acceleron Pharma's key competitors?

Who are Acceleron Pharma's key executives?

Acceleron Pharma's management team includes the folowing people:

  • Francois E. Nader M.D., Independent Chairman of the Board
  • Habib J. Dable, President, Chief Executive Officer, Director
  • Kevin F. McLaughlin, Chief Financial Officer, Senior Vice President, Treasurer
  • Matthew L. Sherman M.D., Executive Vice President and Chief Medical Officer
  • Ravindra Kumar Ph.D, Senior Vice President, Chief Scientific Officer
  • John D. Quisel J.D., Ph.D., Senior Vice President, Business Development, General Counsel and Secretary
  • Jean M. George, Independent Director
  • George S. Golumbeski Ph.D., Independent Director
  • Terrence C. Kearney, Independent Director
  • Tom Maniatis Ph.D., Independent Director

Who owns Acceleron Pharma stock?

Acceleron Pharma's stock is owned by a variety of of retail and institutional investors. Top institutional investors include FMR LLC (12.60%), BlackRock Inc. (9.57%), Vanguard Group Inc. (4.98%), Eagle Asset Management Inc. (3.07%), Westfield Capital Management Co. LP (2.99%) and State Street Corp (2.68%). Company insiders that own Acceleron Pharma stock include Corp /De/ Celgene, Jean George, John D Quisel, John L Knopf, Joseph S Zakrzewski, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Institutional Ownership Trends for Acceleron Pharma.

Who sold Acceleron Pharma stock? Who is selling Acceleron Pharma stock?

Acceleron Pharma's stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co., Granahan Investment Management Inc. MA, FMR LLC, Westfield Capital Management Co. LP, Morgan Stanley, HarbourVest Partners LLC, Jasper Ridge Partners L.P. and Century Capital Management LLC. Company insiders that have sold Acceleron Pharma stock in the last year include Jean George, John D Quisel, John L Knopf, Kevin F Mclaughlin, Matthew L Sherman, Ravindra Kumar, Steven D Ertel and Terrance Mcguire. View Insider Buying and Selling for Acceleron Pharma.

Who bought Acceleron Pharma stock? Who is buying Acceleron Pharma stock?

Acceleron Pharma's stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Eventide Asset Management LLC, Point72 Asset Management L.P., Vanguard Group Inc., VHCP Management II LLC, Pictet Asset Management Ltd., State Street Corp and MARSHALL WACE ASIA Ltd. Company insiders that have bought Acceleron Pharma stock in the last two years include Corp /De/ Celgene and Joseph S Zakrzewski. View Insider Buying and Selling for Acceleron Pharma.

How do I buy Acceleron Pharma stock?

Shares of Acceleron Pharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Acceleron Pharma's stock price today?

One share of Acceleron Pharma stock can currently be purchased for approximately $25.25.

MarketBeat Community Rating for Acceleron Pharma (NASDAQ XLRN)
Community Ranking:  3.7 out of 5 (  )
Outperform Votes:  177 (Vote Outperform)
Underperform Votes:  63 (Vote Underperform)
Total Votes:  240
MarketBeat's community ratings are surveys of what our community members think about Acceleron Pharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Acceleron Pharma (NASDAQ:XLRN) (?)
Ratings Breakdown: 1 Sell Rating, 1 Hold Rating, 13 Buy Ratings
Consensus Rating:Buy (Score: 2.80)
Consensus Price Target: $44.23 (75.17% upside)

Analysts' Ratings History for Acceleron Pharma (NASDAQ:XLRN)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/18/2017FBR & CoReiterated RatingBuyHighView Rating Details
5/17/2017Goldman Sachs Group IncInitiated CoverageSell -> Sell$20.00HighView Rating Details
5/1/2017JMP SecuritiesReiterated RatingOutperform$39.00LowView Rating Details
4/18/2017Credit Suisse Group AGReiterated RatingOutperform$46.00LowView Rating Details
3/14/2017JPMorgan Chase & Co.Initiated CoverageNeutral -> Neutral$33.00HighView Rating Details
3/2/2017Citigroup IncUpgradeNeutral -> Buy$40.00 -> $36.00N/AView Rating Details
3/1/2017InstinetInitiated CoverageBuy -> Buy$58.00N/AView Rating Details
3/1/2017NomuraInitiated CoverageBuyN/AView Rating Details
3/1/2017Oppenheimer Holdings Inc.Set Price TargetBuy$44.00 -> $40.00N/AView Rating Details
3/1/2017CannReiterated RatingOutperformN/AView Rating Details
12/1/2016Leerink SwannSet Price TargetBuy$50.00N/AView Rating Details
8/19/2016BTIG ResearchInitiated CoverageBuy$46.00N/AView Rating Details
8/5/2016Morgan StanleyReiterated RatingBuy$58.00N/AView Rating Details
6/13/2016Barclays PLCBoost Price TargetOverweight$40.00 -> $42.00N/AView Rating Details
6/10/2016Piper Jaffray CompaniesReiterated RatingBuyN/AView Rating Details
2/29/2016Janney Montgomery ScottUpgradeNeutral -> Buy$45.00 -> $39.00N/AView Rating Details
6/9/2015GuggenheimInitiated CoverageNeutralN/AView Rating Details
(Data available from 5/29/2015 forward)


Earnings History for Acceleron Pharma (NASDAQ:XLRN)
Earnings by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Earnings History by Quarter for Acceleron Pharma (NASDAQ XLRN)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/20173/31/2017($0.58)($0.66)$3.38 million$3.71 millionViewListenView Earnings Details
3/1/2017Q416($0.55)($0.51)$3.74 million$3.37 millionViewListenView Earnings Details
11/3/2016Q316($0.53)($0.55)$4.08 million$3.00 millionViewListenView Earnings Details
8/4/2016Q216($0.50)($0.59)$3.77 million$3.20 millionViewListenView Earnings Details
5/5/2016Q116($0.26)$0.14$8.70 million$18.20 millionViewListenView Earnings Details
2/25/2016Q415($0.09)($0.81)$15.70 million$3.80 millionViewListenView Earnings Details
11/4/2015Q315($0.46)($0.36)$4.38 million$4.16 millionViewListenView Earnings Details
8/6/2015Q215($0.49)($0.32)$4.23 million$5.72 millionViewListenView Earnings Details
5/7/2015($0.43)($0.45)$3.98 million$4.42 millionViewN/AView Earnings Details
3/2/2015Q414($0.23)($0.55)$12.90 million$3.74 millionViewListenView Earnings Details
11/7/2014($0.27)($0.25)$17.76 million$3.51 millionViewN/AView Earnings Details
8/12/2014($0.55)($0.54)$4.08 millionViewN/AView Earnings Details
5/15/2014Q114($0.44)($0.30)$2.85 million$3.31 millionViewN/AView Earnings Details
2/26/2014Q413($0.08)($0.64)$13.66 million$11.50 millionViewN/AView Earnings Details
11/6/2013($0.19)($5.62)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Acceleron Pharma (NASDAQ:XLRN)
2017 EPS Consensus Estimate: ($2.67)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.62)($0.51)($0.57)
Q2 20173($0.69)($0.67)($0.68)
Q3 20173($0.71)($0.68)($0.70)
Q4 20173($0.75)($0.69)($0.72)
(Data provided by Zacks Investment Research)


Dividend History for Acceleron Pharma (NASDAQ:XLRN)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Acceleron Pharma (NASDAQ:XLRN)
Insider Ownership Percentage: 12.20%
Institutional Ownership Percentage: 82.57%
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Institutional Ownership by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Insider Trades by Quarter for Acceleron Pharma (NASDAQ:XLRN)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/4/2017Kevin F MclaughlinCFOSell1,700$27.45$46,665.00View SEC Filing  
1/4/2017Matthew L ShermanEVPSell2,000$27.46$54,920.00View SEC Filing  
1/4/2017Steven D ErtelCOOSell2,500$27.44$68,600.00View SEC Filing  
12/30/2016Joseph S ZakrzewskiDirectorBuy4,000$25.50$102,000.00View SEC Filing  
12/8/2016Terrance McguireDirectorSell34,928$30.96$1,081,370.88View SEC Filing  
11/17/2016Jean GeorgeDirectorSell453,505$38.39$17,410,056.95View SEC Filing  
10/10/2016Ravindra KumarSVPSell52,486$33.92$1,780,325.12View SEC Filing  
9/30/2016Jean GeorgeDirectorSell857,145$35.50$30,428,647.50View SEC Filing  
9/21/2016John D QuiselSVPSell45,952$38.05$1,748,473.60View SEC Filing  
9/12/2016John D QuiselSVPSell21,438$32.14$689,017.32View SEC Filing  
7/6/2016John L KnopfCEOSell100,000$33.87$3,387,000.00View SEC Filing  
7/5/2016John L KnopfCEOSell30,501$33.26$1,014,463.26View SEC Filing  
7/5/2016Steven D ErtelCOOSell32,270$34.56$1,115,251.20View SEC Filing  
7/1/2016John L KnopfCEOSell28,022$34.72$972,923.84View SEC Filing  
7/1/2016Kevin F MclaughlinCFOSell25,300$34.66$876,898.00View SEC Filing  
7/1/2016Matthew L ShermanEVPSell26,000$34.74$903,240.00View SEC Filing  
7/1/2016Steven D ErtelCOOSell28,304$34.77$984,130.08View SEC Filing  
5/20/2016John L KnopfCEOSell100,000$33.07$3,307,000.00View SEC Filing  
4/7/2016Matthew L ShermanEVPSell26,000$32.00$832,000.00View SEC Filing  
4/7/2016Steven D ErtelCOOSell32,270$32.00$1,032,640.00View SEC Filing  
1/11/2016Corp /De/ CelgeneMajor ShareholderBuy800,000$40.00$32,000,000.00View SEC Filing  
10/15/2015Matthew L. ShermanEVPSell6,000$23.28$139,680.00View SEC Filing  
10/7/2015John L. KnopfCEOSell19,000$24.38$463,220.00View SEC Filing  
10/7/2015Kevin F. MclaughlinCFOSell7,000$24.38$170,660.00View SEC Filing  
9/16/2015Matthew L. ShermanEVPSell2,000$33.24$66,480.00View SEC Filing  
9/15/2015Ravindra KumarVPSell33,000$35.00$1,155,000.00View SEC Filing  
9/15/2015Steven D. ErtelCOOSell2,000$33.61$67,220.00View SEC Filing  
9/14/2015John D. QuiselSVPSell5,500$33.35$183,425.00View SEC Filing  
9/8/2015John L. KnopfCEOSell19,000$30.20$573,800.00View SEC Filing  
9/8/2015Kevin F. MclaughlinCFOSell6,500$30.16$196,040.00View SEC Filing  
8/18/2015Matthew L ShermanEVPSell7,000$31.13$217,910.00View SEC Filing  
8/14/2015John D QuiselSVPSell5,500$30.83$169,565.00View SEC Filing  
7/20/2015Matthew L ShermanEVPSell6,000$32.46$194,760.00View SEC Filing  
7/15/2015Steven D ErtelCOOSell2,000$31.38$62,760.00View SEC Filing  
7/14/2015John D QuiselSVPSell5,500$30.00$165,000.00View SEC Filing  
7/7/2015John L KnopfCEOSell19,000$29.70$564,300.00View SEC Filing  
7/7/2015Kevin F MclaughlinCFOSell7,000$29.70$207,900.00View SEC Filing  
6/18/2015Matthew L ShermanEVPSell7,000$31.54$220,780.00View SEC Filing  
6/15/2015John D QuiselSVPSell5,500$31.13$171,215.00View SEC Filing  
6/15/2015Steven D ErtelCOOSell2,000$31.11$62,220.00View SEC Filing  
6/8/2015John L KnopfCEOSell19,000$32.51$617,690.00View SEC Filing  
6/8/2015Kevin F MclaughlinCFOSell6,500$32.49$211,185.00View SEC Filing  
5/18/2015Matthew L ShermanEVPSell7,000$32.37$226,590.00View SEC Filing  
5/15/2015Steven D ErtelCOOSell2,000$31.49$62,980.00View SEC Filing  
4/20/2015Matthew L ShermanEVPSell5,000$33.52$167,600.00View SEC Filing  
4/15/2015Steven D ErtelCOOSell2,000$33.58$67,160.00View SEC Filing  
4/7/2015John L KnopfCEOSell20,000$34.87$697,400.00View SEC Filing  
4/7/2015Kevin F MclaughlinCFOSell7,000$34.88$244,160.00View SEC Filing  
3/18/2015Matthew L ShermanEVPSell6,000$41.18$247,080.00View SEC Filing  
3/16/2015John D QuiselSVPSell9,500$41.00$389,500.00View SEC Filing  
3/9/2015John L KnopfCEOSell20,000$40.25$805,000.00View SEC Filing  
3/9/2015Kevin F MclaughlinCFOSell6,500$40.25$261,625.00View SEC Filing  
1/20/2015Matthew L ShermanSVPSell7,000$41.64$291,480.00View SEC Filing  
1/15/2015Steven D ErtelSVPSell2,000$40.58$81,160.00View SEC Filing  
1/12/2015Kevin F MclaughlinCFOSell2,000$40.66$81,320.00View SEC Filing  
1/12/2015Ravindra KumarVPSell1,500$40.80$61,200.00View SEC Filing  
1/7/2015John L KnopfCEOSell20,000$39.62$792,400.00View SEC Filing  
1/7/2015Kevin F MclaughlinCFOSell5,000$39.46$197,300.00View SEC Filing  
1/2/2015Ravindra KumarVPSell4,000$38.46$153,840.00View SEC Filing  
1/2/2015Steven D ErtelSVPSell5,000$38.47$192,350.00View SEC Filing  
12/23/2014Edwin M Kania JrDirectorSell54,350$38.00$2,065,300.00View SEC Filing  
12/18/2014Matthew L ShermanSVPSell5,000$40.16$200,800.00View SEC Filing  
12/12/2014John D QuiselSVPSell4,000$41.35$165,400.00View SEC Filing  
12/9/2014Jean GeorgeDirectorSell97,407$44.90$4,373,574.30View SEC Filing  
12/8/2014John L KnopfCEOSell20,000$43.99$879,800.00View SEC Filing  
12/8/2014Kevin F MclaughlinCFOSell10,000$44.02$440,200.00View SEC Filing  
12/8/2014Tom ManiatisDirectorSell23,400$45.00$1,053,000.00View SEC Filing  
12/1/2014Ravindra KumarVPSell4,000$35.88$143,520.00View SEC Filing  
12/1/2014Steven D ErtelSVPSell7,500$35.87$269,025.00View SEC Filing  
11/18/2014Matthew L ShermanSVPSell5,082$33.76$171,568.32View SEC Filing  
11/13/2014Ravindra KumarVPSell16,000$34.53$552,480.00View SEC Filing  
10/28/2014Tom ManiatisDirectorSell23,400$35.00$819,000.00View SEC Filing  
10/8/2014John L KnopfCEOSell20,000$29.71$594,200.00View SEC Filing  
10/8/2014Matthew L ShermanSVPSell5,082$29.50$149,919.00View SEC Filing  
10/7/2014Kevin F MclaughlinCFOSell10,000$29.25$292,500.00View SEC Filing  
10/1/2014Ravindra KumarVPSell11,000$29.89$328,790.00View SEC Filing  
10/1/2014Steven D ErtelSVPSell10,000$29.66$296,600.00View SEC Filing  
9/30/2014John D QuiselSVPSell7,000$30.01$210,070.00View SEC Filing  
9/18/2014Matthew L ShermanSVPSell5,000$25.48$127,400.00View SEC Filing  
9/12/2014John D QuiselSVPSell2,000$25.43$50,860.00View SEC Filing  
9/9/2014John L KnopfCEOSell20,000$24.46$489,200.00View SEC Filing  
9/9/2014Kevin F MclaughlinCFOSell10,000$24.48$244,800.00View SEC Filing  
9/8/2014John L KnopfCEOSell6,700$24.92$166,964.00View SEC Filing  
9/8/2014Kevin F MclaughlinCFOSell3,300$24.90$82,170.00View SEC Filing  
9/3/2014Matthew L ShermanSVPSell5,000$25.82$129,100.00View SEC Filing  
8/18/2014Matthew L ShermanSVPSell2,500$29.62$74,050.00View SEC Filing  
8/14/2014John D QuiselSVPSell13,000$29.98$389,740.00View SEC Filing  
8/14/2014John L KnopfCEOSell17,500$29.78$521,150.00View SEC Filing  
8/14/2014Kevin F MclaughlinCFOSell10,000$29.78$297,800.00View SEC Filing  
8/14/2014Ravindra KumarVPSell9,000$29.97$269,730.00View SEC Filing  
7/18/2014Matthew L ShermanSVPSell2,500$26.22$65,550.00View SEC Filing  
7/14/2014John D QuiselSVPSell5,000$29.73$148,650.00View SEC Filing  
7/9/2014Matthew L ShermanSVPSell7,500$28.99$217,425.00View SEC Filing  
7/7/2014John L KnopfCEOSell17,500$31.74$555,450.00View SEC Filing  
7/7/2014Kevin F MclaughlinCFOSell10,000$31.72$317,200.00View SEC Filing  
7/1/2014Ravindra KumarVPSell2,000$34.10$68,200.00View SEC Filing  
7/1/2014Steven D ErtelSVPSell10,000$34.09$340,900.00View SEC Filing  
6/26/2014Jean GeorgeDirectorSell10,491$35.01$367,289.91View SEC Filing  
6/24/2014Jean GeorgeDirectorSell25,477$35.16$895,771.32View SEC Filing  
6/20/2014Ravindra KumarVPSell7,000$35.00$245,000.00View SEC Filing  
6/18/2014Matthew L ShermanSVPSell2,500$34.42$86,050.00View SEC Filing  
6/13/2014John D QuiselVPSell9,000$33.94$305,460.00View SEC Filing  
6/11/2014Matthew L ShermanSVPSell7,500$33.23$249,225.00View SEC Filing  
6/9/2014John L KnopfCEOSell15,000$31.65$474,750.00View SEC Filing  
6/9/2014Kevin F MclaughlinCFOSell10,000$31.65$316,500.00View SEC Filing  
5/19/2014John KnopfCEOSell15,000$31.52$472,800.00View SEC Filing  
5/19/2014John QuiselVPSell9,000$31.43$282,870.00View SEC Filing  
5/19/2014Steven ErtelSVPSell10,000$31.52$315,200.00View SEC Filing  
5/5/2014Corp /De/ Celgenemajor shareholderBuy1,100,000$42.86$47,146,000.00View SEC Filing  
5/5/2014Jean GeorgeDirectorSell215,644$42.86$9,242,501.84View SEC Filing  
4/24/2014Edwin Kania, Jr.DirectorSell1,000,000$32.05$32,050,000.00View SEC Filing  
4/22/2014Ravindra KumarVPSell2,000$35.86$71,720.00View SEC Filing  
4/22/2014Steven ErtelSVPSell2,500$35.87$89,675.00View SEC Filing  
1/28/2014Corp /De/ CelgeneMajor ShareholderBuy300,000$50.00$15,000,000.00View SEC Filing  
9/24/2013Corp /De/ CelgeneMajor ShareholderBuy666,667$15.00$10,000,005.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Acceleron Pharma (NASDAQ:XLRN)
Latest Headlines for Acceleron Pharma (NASDAQ:XLRN)
DateHeadline logoAcceleron Pharma (XLRN) Presents At UBS Global Healthcare Conference 2017 - Slideshow - May 23 at 8:11 PM logoAcceleron Pharma Inc (XLRN) Given Buy Rating at FBR & Co - May 19 at 7:16 PM logoAcceleron Pharma (XLRN) Announces Clinical Presentations on Luspatercept at EHA - May 18 at 8:50 AM logoAcceleron Announces Clinical Presentations on Luspatercept at the 22nd Congress of the European Hematology Association - May 18 at 8:50 AM logoAcceleron Pharma Inc (XLRN) Coverage Initiated by Analysts at Goldman Sachs Group Inc - May 17 at 11:38 PM logoAcceleron Pharma Inc (XLRN) Receives Consensus Rating of "Buy" from Analysts - May 15 at 12:04 PM logoAcceleron Pharma, Inc. – Value Analysis (NASDAQ:XLRN) : May 11, 2017 - May 11 at 8:22 PM logoAcceleron Pharma Inc (XLRN) Downgraded by Zacks Investment Research to "Sell" - May 11 at 1:06 PM logoQ2 2017 EPS Estimates for Acceleron Pharma Inc Lowered by Analyst (XLRN) - May 11 at 8:07 AM logoLeerink Swann Weighs in on Acceleron Pharma Inc's Q2 2017 Earnings (XLRN) - May 11 at 7:34 AM logoAcceleron Pharma Inc (XLRN) Expected to Post Q2 2017 Earnings of ($0.69) Per Share - May 10 at 7:50 AM logoFBR & Co Weighs in on Acceleron Pharma Inc's FY2019 Earnings (XLRN) - May 9 at 11:52 AM logoAcceleron Pharma, Inc. breached its 50 day moving average in a Bearish Manner : XLRN-US : May 9, 2017 - May 9 at 9:33 AM logoEdited Transcript of XLRN earnings conference call or presentation 8-May-17 12:00pm GMT - May 8 at 8:14 PM logoHow Celgene Toppled On A Small-Cap Biotech's Ragged Quarter - May 8 at 8:14 PM logoWhy Shares of Biopharma Giant Celgene (CELG) Tumbled Today - May 8 at 8:14 PM logoAcceleron Pharma Inc (XLRN) Issues Earnings Results, Misses Expectations By $0.12 EPS - May 8 at 5:26 PM logoWhy Acceleron Pharma Inc. Is Tumbling Today - May 8 at 4:34 PM logoAcceleron Pharma Reports First Quarter 2017 Operational and Financial Results - May 8 at 8:11 AM logoInvestor Network: Acceleron Pharma Inc to Host Earnings Call - May 8 at 8:11 AM logoAcceleron reports 1Q loss - May 8 at 8:11 AM logo$3.23 Million in Sales Expected for Acceleron Pharma Inc (XLRN) This Quarter - May 7 at 7:52 AM logoLuspatercept Phase 2 Data Presented at the 14th International Symposium on Myelodysplastic Syndromes - May 6 at 3:41 PM logo Analysts Expect Acceleron Pharma Inc (XLRN) to Announce -$0.58 EPS - May 5 at 8:22 PM logoAcceleron Pharma Inc (XLRN) Scheduled to Post Earnings on Monday - May 5 at 8:08 PM logoAcceleron Pharma (XLRN) Receiving Somewhat Positive News Coverage, Study Finds - May 4 at 8:22 AM logoAcceleron Pharma (XLRN) COO to Assume Role as Special Advisor - May 3 at 9:37 AM logoAcceleron Announces Management Change - May 2 at 6:50 PM logoAcceleron Pharma (XLRN) Earning Somewhat Favorable Media Coverage, Report Shows - May 1 at 4:06 PM logoAcceleron to Participate in Two Healthcare Investor Conferences in May - May 1 at 9:58 AM logoLeading Protein Scientist Dr. Asya Grinberg Joins Dragonfly Therapeutics as Head of Biologics - May 1 at 9:58 AM logoAcceleron Pharma (XLRN) Earns Daily Media Sentiment Rating of 0.04 - April 28 at 8:32 AM logoAcceleron Provides Clinical Development Updates on Luspatercept Program - April 27 at 11:30 AM logoAcceleron to Host Webcast to Review First Quarter 2017 Financial and Operational Results on May 8, 2017 - April 26 at 8:10 AM logoSomewhat Favorable Press Coverage Very Unlikely to Impact Acceleron Pharma (XLRN) Share Price - April 25 at 3:12 PM logoAcceleron Pharma Inc (XLRN) Short Interest Update - April 22 at 5:17 PM logoPositive News Coverage Somewhat Unlikely to Affect Acceleron Pharma (XLRN) Stock Price - April 22 at 8:53 AM logoAcceleron Pharma (XLRN) Receiving Positive Media Coverage, Analysis Finds - April 19 at 9:11 AM logoAcceleron Pharma's (XLRN) Outperform Rating Reiterated at Credit Suisse Group AG - April 18 at 5:36 PM logoAcceleron Pharma Inc (XLRN) Receives Consensus Recommendation of "Buy" from Brokerages - April 18 at 12:09 PM logoAcceleron Pharma (XLRN) Receiving Favorable News Coverage, Study Shows - April 16 at 8:50 AM logo Analysts Expect Acceleron Pharma Inc (XLRN) Will Announce Quarterly Sales of $3.23 Million - April 16 at 8:05 AM logo-$0.58 EPS Expected for Acceleron Pharma Inc (XLRN) This Quarter - April 14 at 8:23 PM logoAcceleron Pharma (XLRN) Given Daily Media Sentiment Score of 0.14 - April 13 at 9:26 AM logoFBR & Co Reaffirms Buy Rating for Acceleron Pharma Inc (XLRN) - April 9 at 10:50 PM logoAcceleron Pharma (XLRN) to Highlight Luspatercept Clinical Data at Myelodysplastic Syndromes Conference on 5/6 - - April 8 at 8:11 AM logoAcceleron Pharma (XLRN) to Highlight Luspatercept Clinical Data at Myelodysplastic Syndromes Conference on 5/6 - April 7 at 1:38 PM logoAcceleron Pharma Inc (XLRN) Earns "Buy" Rating from Credit Suisse Group AG - April 7 at 12:18 AM logoAcceleron Pharma Inc Conference Call to Discuss Overview Of CMT And Review Of Phase 2 Clinical Trial scheduled for 11:00 am ET today - April 4 at 5:04 AM logoAcceleron Pharma's (XLRN) "Buy" Rating Reiterated at FBR & Co - March 26 at 7:47 AM



Acceleron Pharma (XLRN) Chart for Monday, May, 29, 2017

This page was last updated on 5/29/2017 by Staff